Effects of beta-amyloid protein on serotoninergic, noradrenergic, and cholinergic markers in neurons of the pontomesencephalic tegmentum in the rat.
The effects on serotoninergic, noradrenergic and cholinergic markers on neurons of the pontomesencephalic tegmentum nuclei were studied in rats following local administration of fibrillar beta-amyloid peptide (Abeta1-40) into the left retrosplenial cortex. Focal deposition of Abeta in the retrosplenial cortex resulted in a loss of serotoninergic neurons in the dorsal and median raphe nuclei. The dorsal raphe nucleus showed a statistically significant reduction of 31.7% in the number of serotoninergic neurons and a decrease (up to 17.38%) in neuronal density in comparison with the same parameters in uninjected controls. A statistically significant reduction of 50.3%, together with a significant decrease of 53.94% in the density of serotoninergic neurons, was also observed in the median raphe nucleus as compared with control animals. Furthermore, a significant reduction of 35.07% in the number of noradrenergic neurons as well as a statistically significant decrease of 56.55% in the density of dopamine-beta-hydroxylase-immunoreactive neurons were also found in the locus coeruleus as compared with the corresponding hemisphere in uninjected controls. By contrast, a reduction of 24.37% in the number of choline acetyltransferase-positive neurons and a slight decrease (up to 22.28%) in the density of cholinergic neurons, which were not statistically significant, was observed in the laterodorsal tegmental nucleus in comparison with the same parameters in control animals. These results show that three different neurochemically defined populations of neurons in the pontomesencephalic tegmentum are affected by the neurotoxicity of Abeta in vivo and that Abeta might indirectly affect serotoninergic, noradrenergic and cholinergic innervation in the retrosplenial cortex.
Gonzalo-Ruiz
A
A
Laboratory of Neuroanatomy, Institute of Neuroscience of Castilla and León, Valladolid University, Nicolas Rabal Street 17, 42003 Soria, Spain. agruiz@ah.uva.es
González
I
I
Sanz-Anquela
J M
JM
D000109:Acetylcholine / Q000502:physiology; D016229:Amyloid beta-Peptides / Q000633:toxicity*; D000818:Animals; D015415:Biomarkers; D001923:Brain Chemistry / Q000187:drug effects; D005260:Female; D008125:Locus Coeruleus / Q000166:cytology / Q000502:physiology; D008845:Microinjections; D009474:Neurons / Q000187:drug effects / Q000502:physiology*; D009638:Norepinephrine / Q000502:physiology; D010446:Peptide Fragments / Q000633:toxicity*; D011149:Pons / Q000166:cytology / Q000502:physiology*; D011903:Raphe Nuclei / Q000166:cytology / Q000502:physiology; D051381:Rats; D017208:Rats, Wistar; D012701:Serotonin / Q000502:physiology; D013681:Tegmentum Mesencephali / Q000166:cytology / Q000502:physiology*
D016229:Amyloid beta-Peptides; D015415:Biomarkers; D010446:Peptide Fragments; C078592:amyloid beta-protein (1-40); D012701:Serotonin; D000109:Acetylcholine; D009638:Norepinephrine